In welcoming Mr. Goolsbee to the Board, Antisense Therapeutics Chairman Bob Moses said “I am extremely pleased that Bill has agreed to join our Board and I am confident he will provide significant practical, as well as strategic value to the Company. Bill’s extensive experience in various aspects of the biopharmaceutical industry is highly relevant to our Company, particularly with respect to assisting us to increase the value of the Company for our shareholders. He has been involved with drug development programs in therapeutics similar to ours and he has experience in the entire regulatory process required for drug development and approval. Bill has also overseen many successful corporate initiatives including M&A. Bill is a perfect fit for our Company”.
ANP Price at posting:
8.9¢ Sentiment: Buy Disclosure: Held
